©2024 Stanford Medicine
A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
Not Recruiting
Trial ID: NCT00631462
Purpose
The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.
Official Title
A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-polycythemia Vera, or Post-essential Thrombocythemia Myelofibrosis
Stanford Investigator(s)
Jason Gotlib
Professor of Medicine (Hematology)
Eligibility
Inclusion Criteria:
* Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia)
* At least 18 years of age.
* ECOG PS 0, 1, or 2.
Exclusion Criteria:
* Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy, corticosteroids, or growth factor treatment within 14 days prior to initiation of study drug.
* Major surgery or radiation therapy within 28 days prior to initiation of study drug.
Intervention(s):
drug: TG101348
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Andrea Linder
6507254047